NO331732B1 - Fremgangsmate for syntese av nukleinsyre - Google Patents
Fremgangsmate for syntese av nukleinsyre Download PDFInfo
- Publication number
- NO331732B1 NO331732B1 NO20022171A NO20022171A NO331732B1 NO 331732 B1 NO331732 B1 NO 331732B1 NO 20022171 A NO20022171 A NO 20022171A NO 20022171 A NO20022171 A NO 20022171A NO 331732 B1 NO331732 B1 NO 331732B1
- Authority
- NO
- Norway
- Prior art keywords
- synthesis
- complementary
- region
- nucleic acid
- chain
- Prior art date
Links
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 264
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 262
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 244
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 239
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 239
- 238000000034 method Methods 0.000 title claims abstract description 142
- 238000006243 chemical reaction Methods 0.000 claims abstract description 147
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 138
- 230000000295 complement effect Effects 0.000 claims description 287
- 125000003729 nucleotide group Chemical group 0.000 claims description 147
- 239000002773 nucleotide Substances 0.000 claims description 143
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 84
- 230000003321 amplification Effects 0.000 claims description 83
- 239000000047 product Substances 0.000 claims description 76
- 238000009396 hybridization Methods 0.000 claims description 55
- 238000006073 displacement reaction Methods 0.000 claims description 54
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 45
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 45
- 239000000523 sample Substances 0.000 claims description 43
- 108020004635 Complementary DNA Proteins 0.000 claims description 38
- 239000007795 chemical reaction product Substances 0.000 claims description 37
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 34
- 102000004190 Enzymes Human genes 0.000 claims description 33
- 108090000790 Enzymes Proteins 0.000 claims description 33
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 29
- 238000001514 detection method Methods 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 27
- 239000011541 reaction mixture Substances 0.000 claims description 22
- 238000002844 melting Methods 0.000 claims description 19
- 230000008018 melting Effects 0.000 claims description 19
- 229960003237 betaine Drugs 0.000 claims description 17
- 102100034343 Integrase Human genes 0.000 claims description 15
- 238000001668 nucleic acid synthesis Methods 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 14
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 13
- 239000000758 substrate Substances 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 230000002776 aggregation Effects 0.000 claims description 6
- 238000004220 aggregation Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical group C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 11
- 230000002194 synthesizing effect Effects 0.000 abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 7
- 239000002585 base Substances 0.000 description 92
- 108020004414 DNA Proteins 0.000 description 29
- 108091008146 restriction endonucleases Proteins 0.000 description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 230000002441 reversible effect Effects 0.000 description 16
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
- 238000001962 electrophoresis Methods 0.000 description 14
- 239000003550 marker Substances 0.000 description 13
- 238000005520 cutting process Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 238000003505 heat denaturation Methods 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000000246 agarose gel electrophoresis Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000006911 enzymatic reaction Methods 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 241001573946 Psara Species 0.000 description 6
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 239000012264 purified product Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- 108010001244 Tli polymerase Proteins 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000012501 chromatography medium Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 108010014594 Heterogeneous Nuclear Ribonucleoprotein A1 Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000138 intercalating agent Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 108010043461 Deep Vent DNA polymerase Proteins 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- -1 however Proteins 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000709744 Enterobacterio phage MS2 Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101150104425 T4 gene Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP1999/006213 WO2000028082A1 (fr) | 1998-11-09 | 1999-11-08 | Procede de synthese d'acide nucleique |
PCT/JP2000/001919 WO2001034790A1 (fr) | 1999-11-08 | 2000-03-28 | Procede de synthese d'un acide nucleique |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20022171D0 NO20022171D0 (no) | 2002-05-07 |
NO20022171L NO20022171L (no) | 2002-07-04 |
NO331732B1 true NO331732B1 (no) | 2012-03-12 |
Family
ID=14237231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20022171A NO331732B1 (no) | 1999-11-08 | 2002-05-07 | Fremgangsmate for syntese av nukleinsyre |
Country Status (9)
Country | Link |
---|---|
KR (1) | KR100612551B1 (zh) |
CN (2) | CN100393875C (zh) |
BR (1) | BR0015382B1 (zh) |
CA (1) | CA2390309C (zh) |
IL (1) | IL149446A0 (zh) |
NO (1) | NO331732B1 (zh) |
RU (1) | RU2252964C2 (zh) |
WO (1) | WO2001034790A1 (zh) |
ZA (1) | ZA200203293B (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6743605B1 (en) | 1998-06-24 | 2004-06-01 | Enzo Life Sciences, Inc. | Linear amplification of specific nucleic acid sequences |
US8445664B2 (en) | 1998-06-24 | 2013-05-21 | Enzo Diagnostics, Inc. | Kits for amplifying and detecting nucleic acid sequences |
ES2464132T3 (es) * | 2000-04-07 | 2014-05-30 | Eiken Kagaku Kabushiki Kaisha | Procedimiento de amplificación de ácido nucleico utilizando como molde ácido nucleico bicatenario |
ATE437225T1 (de) | 2000-09-19 | 2009-08-15 | Eiken Chemical | Verfahren zur polynukleotidsynthese |
KR100806680B1 (ko) * | 2003-11-21 | 2008-02-26 | 한국표준과학연구원 | Pcr용 열순환 반응기의 성능시험용 다중 pcr 조성물 |
PT2412718T (pt) * | 2009-03-26 | 2016-12-30 | Xiamen Amoy Diagnostics Co Ltd | Iniciador em forma de anel utilizado na amplificação de ácido nucleico e a sua utilização |
CN101671674B (zh) * | 2009-03-27 | 2010-09-22 | 郑立谋 | 一种用于核酸扩增的环形引物及其应用 |
TWI600766B (zh) | 2012-08-09 | 2017-10-01 | 財團法人工業技術研究院 | 用於偵測一目標核苷酸序列中之一特定區域的一突變及/或多形性的套組 |
EP2970951B1 (en) | 2013-03-13 | 2019-02-20 | Illumina, Inc. | Methods for nucleic acid sequencing |
SG11201507261WA (en) | 2013-03-15 | 2015-10-29 | Theranos Inc | Nucleic acid amplification |
SG11201507272RA (en) | 2013-03-15 | 2015-10-29 | Theranos Inc | Nuclei acid amplification |
ES2703792T3 (es) * | 2013-11-22 | 2019-03-12 | Orion Diagnostica Oy | Detección de ácidos nucleicos mediante amplificación basada en invasión de hebra |
EP3169793B1 (en) | 2014-07-16 | 2022-07-06 | Tangen Biosciences Inc. | Isothermal methods for amplifying nucleic acid samples |
US11873480B2 (en) * | 2014-10-17 | 2024-01-16 | Illumina Cambridge Limited | Contiguity preserving transposition |
US11559801B2 (en) | 2014-11-03 | 2023-01-24 | Tangen Biosciences, Inc. | Apparatus and method for cell, spore, or virus capture and disruption |
ES2764975T3 (es) * | 2014-12-15 | 2020-06-05 | Cepheid | Amplificación de ácidos nucleicos en base exponencial mayor de 2 |
WO2018132939A1 (zh) * | 2017-01-17 | 2018-07-26 | 中国科学院过程工程研究所 | 一种恒温条件下合成核酸的方法 |
EP3476938B1 (en) * | 2017-09-14 | 2020-05-13 | Zhongke Xinray (Suzhou) Biological Science Technologies Co., Ltd. | Method and kit for synthesizing nucleic acid under constant temperature conditions |
EP3874064A1 (en) | 2018-10-29 | 2021-09-08 | Cepheid | Exponential base-3 nucleic acid amplification with reduced amplification time using nested overlapping primers |
US20230183819A1 (en) | 2019-01-15 | 2023-06-15 | Neogen Food Safety Us Holdco Corporation | Loop-mediated isothermal amplification primers for shiga toxin-producing e. coli (stec) detection |
US20230119314A1 (en) | 2020-02-17 | 2023-04-20 | Neogen Food Safety Us Holdco Corporation | Loop-mediated isothermal amplification primers for vibrio parahaemolyticus detection and uses thereof |
TW202219272A (zh) | 2020-06-12 | 2022-05-16 | 美商夏洛克生物科學公司 | SARS-CoV-2之偵測 |
EP4193363A1 (en) | 2020-08-07 | 2023-06-14 | Oxford Nanopore Technologies plc | Methods of identifying nucleic acid barcodes |
CN113201583B (zh) * | 2021-04-29 | 2022-02-08 | 国科宁波生命与健康产业研究院 | 恒温条件下合成核酸的方法及试剂盒和应用 |
EP4105327A4 (en) * | 2021-04-29 | 2023-01-18 | Ningbo Institute of Life and Health Industry University of Chinese Academy of Sciences | PROCESS FOR THE PREPARATION OF CONSTANT TEMPERATURE NUCLEIC ACIDS AND KIT AND USE THEREOF |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4213029A1 (de) * | 1991-09-26 | 1993-04-01 | Boehringer Mannheim Gmbh | Verfahren zur spezifischen vervielfaeltigung von nukleins aeuresequenzen |
CA2080305A1 (en) * | 1991-10-11 | 1993-04-12 | Linda M. Western | Method for producing a polynucleotide for use in single primer amplification and phosphorothioate-containing oligonucleotides as primers in nucleic acid amplification |
WO1993017127A1 (en) * | 1992-02-20 | 1993-09-02 | The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Boomerand dna amplification |
FR2721945B1 (fr) * | 1994-07-04 | 1996-10-18 | David Fabrice | Accroissement genique, un procede d'amplicication genique isotherme et ses applications |
FR2726277B1 (fr) * | 1994-10-28 | 1996-12-27 | Bio Merieux | Oligonucleotide utilisable comme amorce dans une methode d'amplification basee sur une replication avec deplacement de brin |
ATE317023T1 (de) * | 1999-11-08 | 2006-02-15 | Eiken Chemical | Methode zum nachweis von variationen oder polymorphismen |
-
2000
- 2000-03-28 KR KR1020027005901A patent/KR100612551B1/ko active IP Right Grant
- 2000-03-28 CN CNB008182620A patent/CN100393875C/zh not_active Expired - Lifetime
- 2000-03-28 IL IL14944600A patent/IL149446A0/xx unknown
- 2000-03-28 CA CA2390309A patent/CA2390309C/en not_active Expired - Lifetime
- 2000-03-28 RU RU2002115268/13A patent/RU2252964C2/ru active
- 2000-03-28 WO PCT/JP2000/001919 patent/WO2001034790A1/ja active IP Right Grant
- 2000-03-28 BR BRPI0015382-6A patent/BR0015382B1/pt active IP Right Grant
- 2000-11-07 CN CN2006100803797A patent/CN1876843B/zh not_active Expired - Lifetime
-
2002
- 2002-04-25 ZA ZA200203293A patent/ZA200203293B/xx unknown
- 2002-05-07 NO NO20022171A patent/NO331732B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1876843A (zh) | 2006-12-13 |
RU2252964C2 (ru) | 2005-05-27 |
NO20022171L (no) | 2002-07-04 |
CA2390309A1 (en) | 2001-05-17 |
ZA200203293B (en) | 2003-03-26 |
BR0015382B1 (pt) | 2014-04-29 |
RU2002115268A (ru) | 2004-01-27 |
NO20022171D0 (no) | 2002-05-07 |
KR100612551B1 (ko) | 2006-08-11 |
WO2001034790A1 (fr) | 2001-05-17 |
CN100393875C (zh) | 2008-06-11 |
CN1876843B (zh) | 2012-09-05 |
BR0015382A (pt) | 2002-07-02 |
IL149446A0 (en) | 2002-11-10 |
CA2390309C (en) | 2012-09-25 |
CN1420928A (zh) | 2003-05-28 |
KR20020064896A (ko) | 2002-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO331732B1 (no) | Fremgangsmate for syntese av nukleinsyre | |
JP4139424B2 (ja) | 核酸の合成方法 | |
CN100422323C (zh) | 使用双链核酸为模板扩增核酸的方法 | |
US7374913B2 (en) | Method for synthesizing polynucleotides | |
CN107446919B (zh) | 一种恒温条件下合成核酸的方法及试剂盒 | |
CN109642251B (zh) | 核酸扩增过程中的改进或与核酸扩增过程相关的改进 | |
CN106636071B (zh) | 一种恒温条件下合成核酸的方法 | |
EP1876246A1 (en) | Self-complementary primers used in LAMP gene amplification method | |
EP3476938B1 (en) | Method and kit for synthesizing nucleic acid under constant temperature conditions | |
JP3974441B2 (ja) | 核酸の合成方法 | |
JPWO2002090538A1 (ja) | 核酸を合成する方法 | |
TWI754652B (zh) | 核酸擴增方法中或相關之改良 | |
JP2007325534A (ja) | RecAタンパク質を利用した核酸の等温増幅法 | |
WO2018132939A1 (zh) | 一种恒温条件下合成核酸的方法 | |
AU3330800A (en) | Method of synthesizing nucleic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |